摘要
罕见的基因疾病导致大量的死亡,即使他们“温和”或“非致命”的形式也可产生剧烈的不良的、不适感来影响个人。为开发新型治疗概念,多种基因治疗方法被测试来治疗这些基因疾病。睡美人(SB) 转位子代表了这些可用来稳定表型修正的基因治疗系统中的一种。它是一种可被复苏和优化用于造成转基因体融合的换位基因子的转位子。由于其在许多不同器官中的多功能活性,SB转位酶已被开发用于离体基因传递和体内基因传递,包括近期根据用于肿瘤治疗和视网膜退化治疗的工程化T-细胞推出的临床试验。在此,我们将根据用于基因缺陷稳定修正的SB转位酶系统为罕见基因疾病治疗临床前研究提供一个先进的综述。本文中,影响血液系统、结缔组织、免疫系统、代谢和神经系统等疾病及其使用SB转位酶系统的治疗将被讨论。此外,SB转位酶基因治疗方法的优缺点将被提及。尽管有关基因毒性和有效传递(尤其是应用于大型哺乳动物)的SB转位酶系统的改进是令人满意的,SB转位酶系统对于治疗罕见基因疾病仍前景广阔。
关键词: 动物模型,基因治疗,临床前,罕见基因疾病,睡美人转位酶,体融合,转位子
Current Gene Therapy
Title:The Sleeping Beauty Transposon Vector System for Treatment of Rare Genetic Diseases: An Unrealized Hope?
Volume: 15 Issue: 3
Author(s): Philip Boehme, Johannes Doerner, Manish Solanki, Liu Jing, Wenli Zhang and Anja Ehrhardt
Affiliation:
关键词: 动物模型,基因治疗,临床前,罕见基因疾病,睡美人转位酶,体融合,转位子
摘要: Rare genetic diseases account for a considerable amount of fatalities and even their ‘mild’ or ‘non-lethal’ forms can produce drastic and undesirable discomfort to affected individuals. Various gene therapeutic approaches were tested for developing novel therapeutic concepts to treat these genetic diseases. Sleeping Beauty (SB) transposase represents one of these gene therapeutic systems which can be utilized for stable phenotypic correction. It is a transposable element which was resurrected and optimized for transposing genetic elements resulting in somatic integration of the transgene. Because of its versatile activity in many different organs, SB transposase has been explored for ex-vivo gene delivery and in vivo gene delivery including recently launched clinical trials based on engineered T-cells for tumor therapy and approaches to treat retinal degenerations. Here we will provide a state-of-the-art overview of preclinical studies for treatment of rare genetic diseases based on the SB transposase system for stable correction of the genetic defect. In this review, diseases affecting the blood system, the connective tissue, the immune system, the metabolism, and the nervous system and their treatment utilizing the SB transposase system will be discussed. Moreover, advantages and disadvantages of SB transposase-based gene therapeutic approaches will be mentioned. Although improvements of the SB transposase systems regarding genotoxicity and efficient delivery especially for applications in large mammals are desirable, the SB transposase system remains to hold great promise for curing rare genetic disease.
Export Options
About this article
Cite this article as:
Philip Boehme, Johannes Doerner, Manish Solanki, Liu Jing, Wenli Zhang and Anja Ehrhardt , The Sleeping Beauty Transposon Vector System for Treatment of Rare Genetic Diseases: An Unrealized Hope?, Current Gene Therapy 2015; 15 (3) . https://dx.doi.org/10.2174/1566523215666150126121353
DOI https://dx.doi.org/10.2174/1566523215666150126121353 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections:
Current Biomarkers (Discontinued) Molecular Approaches Target to Immunotherapy for HPV-Associated Cancers
Current Cancer Drug Targets Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Current Drug Therapy Neuroprotection for Amyotrophic Lateral Sclerosis: Role of Stem Cells, Growth Factors, and Gene Therapy
Central Nervous System Agents in Medicinal Chemistry New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Current Medicinal Chemistry Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design Subject Index To Volume-3
Letters in Drug Design & Discovery Radiogenetic Therapy: Strategies to Overcome Tumor Resistance
Current Pharmaceutical Design Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design Hemisynthesis of Selected Embelin Analogs and Investigation of their Proapoptotic Activity Against Cancer Cells
Medicinal Chemistry Benzamide Riboside, a Recent Inhibitor of Inosine 5-Monophosphate Dehydrogenase Induces Transferrin Receptors in Cancer Cells
Current Medicinal Chemistry Selectively Replicating Adenoviruses for Oncolytic Therapy
Current Cancer Drug Targets Integrated Differential Regulatory Analysis Reveals a Novel Prognostic 36-Gene Signature for Gastric Cancer in Asian Population
Combinatorial Chemistry & High Throughput Screening Spectrum of Radiopharmaceuticals in Nuclear Oncology
Current Cancer Drug Targets Merlin, a “Magic” Linker Between the Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival
Current Protein & Peptide Science Protein Degradation Pathways after Brain Ischemia
Current Drug Targets Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
Current Neuropharmacology